Filing Flows › Comparisons › ZBIO vs EVMN
Zenas BioPharma vs Evommune: ZBIO and EVMN compared
Zenas BioPharma is the larger company: $10.0M of revenue in its latest quarter (Q3 2026) against $10.0M for Evommune (Q3 2025).
Where the money goes: ZBIO and EVMN
Zenas BioPharma (ZBIO) · Q3 2026
Zenas BioPharma, Q3 2026: revenue $10.0M, net loss $109M, operating cash flow −$58.0M. The chart follows the revenue to costs, profit and cash.
Evommune (EVMN) · Q3 2025
Evommune, Q3 2025: revenue $10.0M, operating margin -133.3%, net loss $12.5M, operating cash flow −$9.6M. The chart follows the revenue to costs, profit and cash.
| Zenas BioPharma (ZBIO) | Evommune (EVMN) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2025 |
| Revenue | $10.0M | $10.0M |
| Operating margin | n/m | -133.3% |
| Net earnings | −$109M | −$12.5M |
| Net margin | — | -124.8% |
| Operating cash flow | −$58.0M | −$9.6M |
Questions
Which is bigger, Zenas BioPharma or Evommune?
Zenas BioPharma is the larger company: $10.0M of revenue in its latest quarter (Q3 2026) against $10.0M for Evommune (Q3 2025).
More: Zenas BioPharma earnings · how Zenas BioPharma makes money · Evommune earnings · how Evommune makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Dec 11, 2025). Fiscal quarters can end on different dates. Not investment advice.